Board of Directors

Joel is a mission driven leader with more than twenty five years of experience in successfully building, growing and leading medical technology companies. He has a focus on executing growth strategies with operating discipline to exceed goals and develop market leadership in a patient first culture of strong values and ethics. Joel has extensive functional expertise and experience in General Management, Sales, Marketing, M&A, and Operations.

Previously Joel lead the $400M+ Cardiac Rhythm Management and Neuromodulation business as President for Integer Holdings LLC, a $1.2B publicly traded medical device contract development and manufacturing company, where he oversaw commercial execution with a focus on operational efficiencies and margin control. He also served as the President of the Americas Division for St. Jude Medical Inc., a $5.5B global medical device leader. In this role Joel lead the $3B commercial organizations for the electrophysiology, cardiology, structural heart, cardiac rhythm management and neuromodulation businesses in the Americas. In addition to a number of other leadership roles at St. Jude Medical, Joel also served as one of the founding members of the Atrial Fibrillation Division management team which he helped lead and grow to more than $700M in revenue.

Joel holds a Masters in Business Administration degree from the Carlson School of Management at the University of Minnesota.

Lisa Andrade joins NeuroPace with over 25 years of experience in both large and early-stage medtech, software and technology companies. Currently, Ms. Andrade is CEO of M33, an executive coaching and leadership development firm, which she founded in 2018. Prior to founding M33, she served as Chief Marketing Officer at St. Jude Medical, a global medical device company, which was acquired by Abbott in 2017. Ms. Andrade has held numerous executive leadership positions in engineering, research, product development, strategy, product management, marketing, healthcare economics and sales. She has been instrumental in the development and commercialization of numerous innovative medical devices and software products in the healthcare market and has been awarded multiple patents. Lisa received her B.S. in biomedical and electrical engineering and an M.S. in biomedical engineering from Duke University as well as an MBA from The Wharton School of Business at the University of Pennsylvania.

Frank Fischer has served as the Chairman of our board of directors since November 1997. From 2000 to July 2019, Mr. Fischer served as our President and Chief Executive Officer and as a part-time employee of ours from July 2019 to January 2020. Prior to that, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a medical device company, from 1998 to 1999, and served on Heartport’s board of directors from 1992 to 1999. Previously, Mr. Fischer was President and Chief Executive Officer of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Mr. Fischer has served as a member of the board of directors of Nevro, Inc., a medical device company, since 2012. Mr. Fischer received a B.S. in Mechanical Engineering and a M.S. in Management from Rensselaer Polytechnic Institute. We believe Mr. Fischer is qualified to serve on our board of directors because of his extensive experience with medical device companies and the historical knowledge and continuity he brings to our board of directors.

Rakhi Kumar has served as a member of our board of directors since April 2021. Ms. Kumar was appointed Chief Accounting Officer at Roivant Sciences (Nasdaq: ROIV) in 2018, following her role as Vice President, Finance and External Reporting from 2015 to 2018. Her experience preceding Roivant includes leading external reporting, corporate and technical accounting at The Medicines Company from 2013 to 2015 and working in assurance services at Ernst and Young.

Ms. Kumar is a member of the Financial Accounting Standards Board’s (FASB) Small Business Advisory Committee (SBAC) and serves on the board of directors for Roivant Social Ventures (RSV). She is a licensed Certified Public Accountant in the United States, a Chartered Professional Accountant in Ontario, Canada, and holds an M.S. in Accounting and Taxation from the University of Hartford.

Joseph S. Lacob has served as a member of our board of directors since 1997. Since 2010, Mr. Lacob has served as Co-Executive Chairman and Chief Executive Officer of the Golden State Warriors. Mr. Lacob has served as a director of Align Technology, Inc. a global medical device company, since 1997. Mr. Lacob earned a B.S. from the University of California, Irvine, an M.P.H. from the University of California, Los Angeles, and an M.B.A from the Stanford Graduate School of Business. We believe Mr. Lacob is qualified to serve on our board of directors because of the historical knowledge and continuity he brings to our board of directors.

Renee Ryan has served as a member of our board of directors since 2013. Since August 2019, Ms. Ryan has served as Chief Executive Officer at Cala Health, Inc., a medical technology company. From 2011 to August 2019, Ms. Ryan served as Vice President, Investments, at Johnson & Johnson Development Corp., the venture investing arm of Johnson &Johnson. From 2008 to 2011, Ms. Ryan served as Managing Director at Robert W. Baird & Co., a private equity firm and financial services company. We believe Ms. Ryan is qualified to serve on our board of directors because of her leadership experience and extensive experience in the medical device industry.

Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York's Columbia University Center for Law & Economics, where he majored in global equity markets. Uri Geiger brings extensive entrepreneurial, management and investment know-how having created and built many successful medical device enterprises. Dr. Geiger served as Chairman and Board member of over 20 medical device companies including a number of NASDAQ listed companies.